Search results
Showing 961 to 975 of 1401 results for 0
i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department (MIB38)
NICE has developed a medtech innovation briefing (MIB) on i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department
Slide sheets for moving or repositioning a person: late-stage assessment (HTG745)
Late-stage assessment (LSA) guidance on slide sheets for moving or repositioning a person.
Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)
This interim process statement sets out to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs
Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)
Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.
Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)
This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer. It does not cover pregnant women.
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.
Repetitive transcranial magnetic stimulation for depression (HTG396)
Evidence-based recommendations on repetitive transcranial magnetic stimulation for depression. This involves placing an electromagnetic coil against the scalp, which creates electric currents in certain parts of the brain.
Radiofrequency tissue reduction for turbinate hypertrophy (HTG343)
Evidence-based recommendations on radiofrequency tissue reduction for turbinate hypertrophy. This involves using radiofrequency energy to close blood vessels that can cause swelling and destroy excess tissue.
View recommendations for HTG343Show all sections
Microwave ablation for atrial fibrillation in association with other cardiac surgery (HTG73)
Evidence-based recommendations on microwave ablation for atrial fibrillation in association with other cardiac surgery. This involves scarring the heart tissue using heat produced from microwave energy to interrupt abnormal electrical signals.
View recommendations for HTG73Show all sections
Sections for HTG73
NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)
Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.
In development Reference number: GID-TA10882 Expected publication date: TBC
This quality standard covers preventing, assessing, diagnosing and managing skin cancer (melanoma and non-melanoma skin cancer). It describes high-quality care in priority areas for improvement.
View quality statements for QS130Show all sections
Sections for QS130
NICE has developed a medtech innovation briefing (MIB) on the Shiley Endotracheal Tube with TaperGuard Cuff .